IL98258A - Impotence treatment preparations containing K.U 640,25 - Google Patents

Impotence treatment preparations containing K.U 640,25

Info

Publication number
IL98258A
IL98258A IL9825891A IL9825891A IL98258A IL 98258 A IL98258 A IL 98258A IL 9825891 A IL9825891 A IL 9825891A IL 9825891 A IL9825891 A IL 9825891A IL 98258 A IL98258 A IL 98258A
Authority
IL
Israel
Prior art keywords
compound
impotence
use according
acid addition
acceptable acid
Prior art date
Application number
IL9825891A
Other languages
English (en)
Hebrew (he)
Other versions
IL98258A0 (en
Inventor
George Mclean Milne
Michael Grant Wyllie
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL98258A0 publication Critical patent/IL98258A0/xx
Publication of IL98258A publication Critical patent/IL98258A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Harvester Elements (AREA)
  • Saccharide Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Tone Control, Compression And Expansion, Limiting Amplitude (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IL9825891A 1990-05-31 1991-05-24 Impotence treatment preparations containing K.U 640,25 IL98258A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53149490A 1990-05-31 1990-05-31

Publications (2)

Publication Number Publication Date
IL98258A0 IL98258A0 (en) 1992-06-21
IL98258A true IL98258A (en) 1996-01-31

Family

ID=24117862

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9825891A IL98258A (en) 1990-05-31 1991-05-24 Impotence treatment preparations containing K.U 640,25

Country Status (15)

Country Link
EP (1) EP0459666B1 (da)
JP (1) JP2522609B2 (da)
KR (1) KR930010582B1 (da)
AT (1) ATE113839T1 (da)
AU (1) AU620282B2 (da)
CA (1) CA2043440C (da)
DE (1) DE69105040T2 (da)
DK (1) DK0459666T3 (da)
HU (1) HU208076B (da)
IE (1) IE63837B1 (da)
IL (1) IL98258A (da)
MY (1) MY106528A (da)
NZ (1) NZ238339A (da)
PT (1) PT97785B (da)
ZA (1) ZA914135B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4223800A1 (de) * 1992-07-20 1994-01-27 Cassella Farbwerke Mainkur Ag Verwendung von 1.2.5-Oxadiazol-2-oxiden zur Behandlung erektiler Dysfunktionen
EP0611248B1 (en) * 1993-02-10 2000-03-22 B.M.R.A. Corporation B.V. Pharmaceutical composition for treating impotence containing an alpha-1-inhibitor and an alpha-2 inhibitor
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
NZ297278A (en) 1994-11-16 1999-06-29 Synaptic Pharma Corp 4-aryl dihydropyrimidine derivatives end medicaments
US6268369B1 (en) 1994-11-16 2001-07-31 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
SK124397A3 (en) * 1995-03-14 1998-12-02 Vivus Inc Method and kit for preventing erectile dysfunction
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6228861B1 (en) 1995-11-16 2001-05-08 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
TR199802282T2 (xx) * 1996-05-10 1999-03-22 Icos Corporation Karbolin t�revleri.
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6245773B1 (en) 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
PT849266E (pt) * 1996-12-20 2007-03-30 Heumann Pcs Gmbh Nova forma polimorfa de mesilato de doxazosina (forma iii)
EP0849264A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von doxazosinmesylat (Form I)
EP0849265A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von Doxazosin-Mesylat (Form II)
AU759825B2 (en) * 1997-12-16 2003-05-01 Pfizer Products Inc. Combination effective for the treatment of impotence
DE19800214A1 (de) 1998-01-06 1999-07-15 Knoll Ag Verfahren zur Herstellung von Doxazosin-Mcsylat in einer als Form A bezeichneten Kristallmodifikation und ein Zwischenprodukt dafür
US6268377B1 (en) * 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
RU2135195C1 (ru) * 1998-12-17 1999-08-27 Овсюк Валерий Григорьевич Способ получения материала, содержащего клетки предстательной железы, материал, содержащий клетки предстательной железы, и способы лечения фиброматоза матки, хронического простатита и нарушений мужской половой функции методом трансплантации
US6680323B2 (en) 1998-12-23 2004-01-20 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6274585B1 (en) 1998-12-23 2001-08-14 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
GB0008332D0 (en) * 2000-04-04 2000-05-24 Pfizer Ltd Treament
US6521647B2 (en) 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
DE60126265T2 (de) * 2000-05-12 2007-10-31 Novalar Pharmaceuticals, Inc. Zusammensetzung bestehend aus Phentolaminmesylat und deren Verwendung
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925837A (en) * 1984-09-14 1990-05-15 Synthelabo Pharmaceutical compositions

Also Published As

Publication number Publication date
KR930010582B1 (ko) 1993-10-30
HUT58520A (en) 1992-03-30
HU911810D0 (en) 1991-12-30
EP0459666B1 (en) 1994-11-09
JP2522609B2 (ja) 1996-08-07
ATE113839T1 (de) 1994-11-15
HU208076B (en) 1993-08-30
IE911842A1 (en) 1991-12-04
DE69105040D1 (de) 1994-12-15
PT97785A (pt) 1992-02-28
EP0459666A2 (en) 1991-12-04
AU7807791A (en) 1991-12-05
IE63837B1 (en) 1995-06-14
NZ238339A (en) 1997-07-27
KR910019618A (ko) 1991-12-19
DE69105040T2 (de) 1995-03-23
AU620282B2 (en) 1992-02-13
CA2043440A1 (en) 1991-12-01
DK0459666T3 (da) 1994-12-05
JPH04235917A (ja) 1992-08-25
EP0459666A3 (en) 1992-06-03
ZA914135B (en) 1993-01-27
PT97785B (pt) 1999-01-29
MY106528A (en) 1995-06-30
CA2043440C (en) 1996-07-30
IL98258A0 (en) 1992-06-21

Similar Documents

Publication Publication Date Title
US5270323A (en) Method of treating impotence
CA2043440C (en) Method of treating impotence
US5773457A (en) Compositions
KR100331754B1 (ko) 동물의발기부전또는불감증치료용약제조성물
US5059603A (en) Method and composition for treating impotence
DE69933128T2 (de) Pharmazeutische zusammensetzungen zur behandlung von erektiler dysfunktion
US5583144A (en) Methods for treating erectile impotence
CZ20013455A3 (cs) Vysoce účinné dihydroergotaminové prostředky
US6124461A (en) Compounds, compositions, and methods for treating erectile dysfunction
US6589990B1 (en) Methods and compositions for misoprostol compound treatment of erectile dysfunction
AU4000699A (en) Compositions comprising organic mono- or dinitrate for treating impotence
Monti et al. Enhancement of transdermal penetration of dapiprazole through hairless mouse skin
DK167559B1 (da) Buprenorphinholdigt farmaceutisk suppositorium
US5336678A (en) Use of minoxidil for treating erectile impotence
US6365590B1 (en) Compounds, compositions and methods for treating erectile dysfunction
JP2001064205A (ja) 製剤組成物
US5561154A (en) Treatment of acute urinary retention
US4581359A (en) Pharmacological treatments with N-7-substituted derivatives of theophylline
EP1132094A1 (en) Percutaneously administrable preparations containing cerebral function activators
KR100649860B1 (ko) 알프로스타딜 경점막 및 경피흡수제제
KR20050057245A (ko) 남성 발기 부전을 치료하는 방법
AU678996C (en) Method of treating sexual dysfunction in animals with an H agonist

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees